Stockwinners Market Radar for July 05, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:41 EDT Ascent Capital to withdraw Series A common stock from listing on Nasdaq - Ascent Capital has voluntarily notified Nasdaq of its intent to withdraw its Series A common stock, par value 1c per share, from listing on Nasdaq Global Select Market. Ascent announced that it supplemented its initial notice with information regarding the July 1 deficiency notice. On July 15, following a ten-day period that commences after Ascent provided notice of its intent to delist to Nasdaq, Ascent intends to file with Nasdaq and the U.S. Securities and Exchange Commission, a Form 25 relating to the delisting of its Series A common stock. It is anticipated that the delisting will become effective on July 25, ten days after the filing date of the Form 25, and its Series A common stock will no longer trade on Nasdaq effective on such date. Ascent expects its Series A common stock to be quoted and traded on the OTC Markets promptly after the effectiveness of the delisting from Nasdaq, although it cannot assure that this will be the case. Ascent does not expect the Nasdaq delisting or SEC deregistration to adversely affect Ascent's business operations or the pending restructuring of its wholly owned subsidiary, Monitronics under Chapter 11 of the U.S. Bankruptcy Code, nor does Ascent believe that the delisting will adversely impact Ascent's proposed participation in the restructuring of Monitronics, including the proposed merger of Ascent into Monitronics. As previously disclosed, on November 26, 2018, Ascent received notification from the Listing Qualifications Department of Nasdaq that the market value of the publicly held shares of Ascent's Series A common stock for the last 30 consecutive business days was less than $15M, which is the minimum market value of publicly held shares necessary to qualify for continued listing on Nasdaq under Listing Rule 5450. The letter further indicated that Ascent had a grace period through May 28 to regain compliance. Because Ascent did not regain compliance with the requirement before the grace period expired, it received a letter from Nasdaq on May 29, that Ascent's Series A common stock would be delisted, absent an appeal by Ascent to stay the delisting. Ascent originally intended to appeal Nasdaq's determination to delist Ascent's Series A common stock at a hearing scheduled for August 1, and Ascent's management and board assessed possible actions to regain compliance with the requirement, and carefully reviewed and considered a number of factors, including Ascent's current financial condition and the pendency of the restructuring of its wholly-owned subsidiary, Monitronics. Following such assessments, the board, with the support and recommendation of Ascent's management, has concluded that the expenditures of time and resources necessary to regain compliance with the requirement and to prepare for the August hearing, when considered together with the tenuous uncertainty of Ascent's ability to present a plan satisfactory to Nasdaq for regaining compliance, would not be in the best interests of Ascent's stockholders and that all such resources could be better focused on Monitronics' pending restructuring. For such reasons, the board has determined to voluntarily delist the Series A common stock from Nasdaq.

16:25 EDT AAC Holdings submits business plan to NYSE - On Monday July 1, 2019, AAC Holdings submitted a plan to the New York Stock Exchange, Inc. regarding the company's efforts to improve its total market capitalization, following notice on May 17, 2019 from the NYSE that the company's average market capitalization was less than the required $50M over a consecutive 30 trading-day period and that the most recently reported stockholders' equity of the company was also less than $50M. By submitting the plan, the company will be eligible for the NYSE to permit an 18-month cure period with respect to the total market capitalization requirement and a six-month cure period with respect to the requirement that the company's share price exceed more than $1.00 for a 30-day trading period. The company received a notice from the NYSE with respect to the latter requirement on July 3, 2019. The NYSE notifications and plan response processes do not affect the company's business operations, its United States Securities and Exchange Commission reporting requirements, or its debt agreements.

16:03 EDT D.E. Shaw reports 5.1% passive stake in Stamps.com - In a regulatory filing, D.E. Shaw disclosed a 5.1% stake in Stamps.com, which represents 887,714 shares. The filing does not allow for activism.

13:41 EDT Verant Venture Capital VI reports 14.7% passive stake in Akero Therapeutics - In a regulatory filing, Verant Venture Capital VI disclosed a 14.7% stake in Akero Therapeutics, which represents over 4M common shares. The filing does not allow for activism.

12:00 EDT New Home Company falls -6.3% - New Home Company is down -6.3%, or -29c to $4.38.

12:00 EDT VelocityShares 3x Inv Natural Gas ETN falls -18.6% - VelocityShares 3x Inv Natural Gas ETN is down -18.6%, or -$30.88 to $135.15.

12:00 EDT Gol Linhas rises 17.9% - Gol Linhas is up 17.9%, or $3.21 to $21.13.

11:40 EDT Trump says working on 'favored-nations clause' to lower drug prices - President Trump told reporters at the White House that his administration is working on a "favored-nations clause," or a system that would allow the U.S. to buy drugs based on the lowest prices paid by other countries. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

10:00 EDT Yirendai falls -10.0% - Yirendai is down -10.0%, or -$1.41 to $12.66.

10:00 EDT Gol Linhas rises 10.4% - Gol Linhas is up 10.4%, or $1.86 to $19.78.

10:00 EDT VelocityShares 3x Long Natural Gas ETN rises 14.9% - VelocityShares 3x Long Natural Gas ETN is up 14.9%, or $2.34 to $18.02.

09:47 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs falls -8.5% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is down -8.5%, or -$5.04 to $53.94.

09:47 EDT Direxion Daily Gold Miners Bear 3X ETF rises 8.4% - Direxion Daily Gold Miners Bear 3X ETF is up 8.4%, or 93c to $11.98.

09:47 EDT VelocityShares 3x Long Natural Gas ETN rises 14.2% - VelocityShares 3x Long Natural Gas ETN is up 14.2%, or $2.22 to $17.90.

09:19 EDT SiteOne Landscape acquires wholesale distribution of L.H. Voss Materials Dublin - SiteOne Landscape Supply announced the acquisition of the wholesale distribution business of L.H. Voss Materials Dublin and its affiliates, Mt. Diablo Landscape Centers and Clarks Home & Gardens, with five locations across the east bay in northern California focused on the distribution of hardscapes and landscape supplies to landscape professionals.

09:13 EDT Tix Corp urges stockholders to disregard communications from Haren Bhakta, HSB - The company said, "You may be contacted by, receive a letter from or see a press release made by a dissident stockholder, Haren S. Bhakta or his fund HSB Capital Partners, L.P., announcing an intention to nominate individuals to our board of directors. Tix Corporation urges you to disregard communications and materials from Mr. Bhakta, HSB or their affiliates. During the past two years, Tix has been forced to expend valuable resources defending itself and its stockholders from Mr. Bhakta's destructive actions, which, as detailed below, have included harassment of Tix employees, interference with Tix's business, and other dubious behavior. Mr. Bhakta now seeks to nominate himself and other unqualified individuals for election to the Tix board of directors at the 2019 annual meeting of stockholders. Tix previously notified HSB that its notice purporting to nominate Mr. Bhakta and these other unqualified individuals is incomplete and deficient pursuant to our bylaws. Tix therefore wishes to advise stockholders that because of the aforesaid deficiencies, any proxy or vote with respect to HSB's nominees, including Mr. Bhakta, may not be counted at our 2019 annual meeting of stockholders. Tix anticipates that the 2019 annual meeting of stockholders will be held in September, where stockholders will be asked to vote upon the election of directors to the board as well as ratifying the selection of an auditor for the fiscal year...Tix will remain focused on its growth plan and on enhancing stockholder value for the benefit of all concerned and will not get distracted from its goals by Mr. Bhakta or HSB. Tix urges stockholders to assist it in this effort by disregarding Mr. Bhakta to dissuade him from continuing his destructive actions."

08:57 EDT Fly Intel: Pre-market Movers - HIGHER: DBV Technologies (DBVT), up 16% after Bloomberg reports there are expectations that the company will submit another biologic license application for its Viaskin Peanuts allergy patch to the FDA sometime during Q3... Karyopharm (KPTI), up 12% after the FDA approved oral Xpovio, a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents and an anti-CD38 monoclonal antibody... Grifols (GRFS), up 4% after announcing that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the FDA. LOWER: Qualcomm (QCOM), down 3% after Bloomberg reported the company lost in its attempt to put on pause a U.S. judge's ruling that the company engaged in anti-competitive practices as Qualcomm pursues an appeal... Celyad (CYAD), down 5% after reporting preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials assessing safety and clinical activity of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer... Senseonics (SENS), down 3% after Raymond James analyst Jayson Bedford downgraded the stock to Market Perform from Outperform. The analyst says the company's "persistent headwinds" leave him "less patient" with respect to the shares.

08:33 EDT Acer Therapeutics expects restructuring to extend cash runway through 2020

08:32 EDT Acer Therapeutics says pre-commercial activities of EDSIVO have been halted - Acer Therapeutics announced a corporate restructuring and update on its pipeline programs. Acer's headcount has been reduced from 48 to 19 employees and pre-commercial activities of EDSIVO have been halted. The restructuring is expected to provide the resources needed for Acer to conduct its planned business operations through 2020. Acer intends to pursue discussions with the U.S. Food and Drug Administration regarding its previously announced Complete Response Letter for Acer's New Drug Application for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome, and to continue the development of Acer's additional pipeline programs, including ACER-001 and osanetant. "While we are disappointed by the CRL, we intend to continue our dialogue with the FDA to fully understand its response and work toward our goal of approval of EDSIVO for confirmed COL3A1+ vEDS patients, who currently have no approved treatment options," said Chris Schelling, CEO and Founder of Acer. "Nevertheless, in light of the CRL it was necessary to reduce our expenses, extend our cash runway, and focus our resources on a potential path forward for EDSIVO as well as continued development of our other pipeline opportunities."

08:24 EDT Yamana Gold reduces board of directors to nine - The company said, "The streamlined organizational structure will facilitate improved communication and information sharing between sites and head office and reflects the smaller asset portfolio resulting from the sale of Chapada. Consistent with these changes, and to better reflect a new size and scale, the Company also announced today a reduction in the size of its Board of Directors the result of which is that the Board will now be reduced to nine with eight independent directors. This is part of a broader strategy intended to ensure the Company has the proper skills and diversity as well as effectiveness in management and director oversight. In order to facilitate this strategy, two of the directors of the Company, Messrs Nigel Lees and Robert Gallagher, have agreed to step down from the Board. While Mr. Lees has been a long-serving member of the Board, he had reached retirement age and chose to make way for a new generation of directors. As for Mr. Gallagher, he has been instrumental in the recent efforts of the Company to pursue operational excellence, which have now been fulfilled. Both Messrs Lees and Gallagher felt the oversight of the Company was now well in hand and volunteered to step down from the Board to facilitate the strategy that smaller and more streamlined is better. For a transition period of time, Mr. Gallagher has indicated that he will continue to be available to the Company for any advice or support it may need. The Company would like to extend its deep gratitude and appreciation to Messrs Lees and Gallagher for their significant contribution to Yamana... In addition, as a result of these immediate changes, the Company now maintains an unparalleled gender diversity mix with 50% female directors among its independent directors."

08:21 EDT Yamana Gold completes sale of Chapada, begins debt repayment process - YAMANA GOLD announced it has completed the sale of its wholly-owned Chapada mine to Lundin Mining Corporation for total consideration of over $1B. Yamana has received the initial upfront cash consideration of $800M on closing. In addition to the initial cash payment, consideration also includes a $100M cash payment contingent on the development of a pyrite roaster at Chapada by Lundin, a two per cent net smelter return royalty on the Suruca gold project in the Chapada complex, and a right to receive up to $125M in additional cash consideration based on the price of gold over the five-year period from the date of closing as follows: $10M per year for each year over the next five years where the gold price averages over $1,350 per ounce, up to a maximum cash payment of $50M. An additional $10M per year for each year over the next five years where the gold price averages over $1,400 per ounce, up to a maximum cash payment of $50M. An additional $5M per year for each year over the next five years where the gold price averages over $1,450 per ounce, up to a maximum cash payment of $25M. While the Company recognized significant cash consideration from the sale, representing fair value, there is also considerable optionality from the non-cash components, a very substantial portion of which relates to gold and gold price, the result of which is that the Company preserves leverage to gold that it would otherwise have produced at Chapada without incurring operational risk. The Gold Price Instrument is structured as a separate right that increases in value when the price of gold rises. The Gold Price Instrument entitles the Company to be paid according to its terms, summarized above. Concurrently with the closing, the Company is using $385M to repay outstanding indebtedness under the revolving credit facility, the balance outstanding on June 30th and on close of the transaction. The remaining $415M in upfront cash consideration is being used by the Company to offer to prepay its senior notes issued in March 2012 and June 2013 on a pro rata basis. These Prepay Offers have been distributed simultaneously with the closing of the Chapada sale. The Prepay Offers indicated that in the event cash consideration remains available, the balance will be used to prepay indebtedness under the Company's senior notes issued in June 2014 and December 2017. The reduction in net debt immediately lowers Yamana's Net Debt/EBITDA leverage ratio, a measure of financial strength, to 1.5x. The Company continues to target Net Debt/EBITDA of 1.0x by the end of 2021. Beyond the leverage improvements, the Company will significantly reduce the annual carrying cost of interest on debt by approximately $40M, freeing up cash for other uses or to further improve its net debt position. As part of the debt Prepay Offers, the Company expects to pay a premium to reference or trading levels of its notes. The annual reduction of interest savings and, further, the present value of interest savings will be a multiple of the total premium offered in the prepayment transaction. Importantly, the resultant cash flow margin increases from interest savings improves the Company's resiliency and flexibility.

08:10 EDT II-VI, Finisar announce deadline for election of form of merger consideration - II-VI Incorporated (IIVI) and Finisar Corporation (FNSR) jointly announced today that, in connection with II-VI's anticipated and pending acquisition of Finisar, the deadline for Finisar stockholders to elect the form of merger consideration they wish to receive in the Merger has been set for 5:00 p.m., New York time, on July 15, 2019. Establishing the date of the Election Deadline is not intended, however, to indicate the expected timing of approval of the Merger by the State Administration for Market Regulation of the People's Republic of China.

08:06 EDT Tyme Technologies presents updated data from TYME-88-Panc Phase II study - Tyme Technologies announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile. The data from the TYME-88-Panc study were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer. Updated results from the ongoing multicenter open-label Phase II TYME-88-Panc study involved 49 heavily pretreated patients with radiographically progressive metastatic pancreatic cancer who had significant disease related morbidity before receiving TYME's investigational agent SM-88. More than 80% of patients had received at least two prior lines of therapy. Of the 49 patients, 38 patients were evaluable for efficacy, as defined in the protocol. TYME-88-Panc is a two-part study in which Part 1 was intended to determine optimal dosing and assess if early clinical benefit supported further development of SM-88 in pancreatic cancer. This study is being performed under a TYME IND with input from the FDA prior to study initiation. In this study, based on information available as of April 25, 2019, the median overall survival of evaluable patients was 6.4 months. Certain efficacy indicators correlated with greater OS, including achieving SD or better and decreases in CTCs. A RECIST clinical benefit rate of stable disease or better was achieved by 44% of patients with available imaging. Notably, patients achieving stable disease or better demonstrated a statistically significant improvement in survival with a 92% reduction in risk of death. The CBR was durable with majority of these patients remaining in stable disease or better at more than 7 months after receiving treatment with SM-88. The measurement of CTCs is emerging as an important prognostic indicator in patients with pancreatic cancer. This is now the second TYME study in cancer patients showing that SM-88 reduces CTCs. In a previous study of patients with prostate cancer, SM-88 treatment was also associated with a reduction in CTC count. In the TYME-88-Panc study, a median reduction of 63% in CTC burden was observed in evaluable patients. Importantly, patients with available results reaching an 80% reduction or greater in CTCs demonstrated a 60% decrease in risk of death. In addition to these findings from the TYME-88-Panc study, data were also presented on subgroup analyses. TYME identified several screening criteria that were associated with rapidly declining prognostic factors defined as greater than 2 lines of prior therapy; age greater than 75 years old; albumin less than 3.5 g/dl. Patients with no indicators of poor prognosis had a better trend in survival. TYME identified key sub-groups of patients who performed better. Patients with 1 or 2 prior lines of therapy had a better trend in survival. Female patients had a statistically significant trend toward better survival. These encouraging findings warrant further clinical evaluation of these subgroups. As of April 25, 2019, the study reported that SM-88 was well tolerated with only 4.0% of patients who experienced serious adverse events deemed at least possibly related to SM-88. One patient with reported SAEs continued on treatment. The TYME-88-Panc research results are from an investigational study. SM-88 is not approved for the treatment of patients with any disease condition.

08:02 EDT Rice Team says Egan-Jones recommends EQT shareholders vote for all nominees - The Rice Team, shareholders of EQT Corporation, announced that Egan-Jones Ratings Company, has issued a report recommending that EQT shareholders vote for all of the Rice Team nominees on the WHITE universal proxy card. Egan-Jones' conclusion is in line with the recommendation of Institutional Shareholders Services for EQT shareholders to vote for all of the Rice Team nominees, as well as public statements of support from EQT's three largest actively managed shareholders - T. Rowe Price, D.E. Shaw and Kensico Capital Management - in favor of the Rice Team nominees and plan for EQT. In making its recommendation, Egan-Jones noted: "In our view, the incumbent Board and management fall short of the operational skillset to deliver long-term shareholder value. We believe that leadership with a true understanding of energy engineering rather than financial engineering is critical in the execution of strategies that will unlock potential shareholder value...We believe that the [Rice Team] Nominees, if elected, will pursue the realization of the expected benefits of the EQT-Rice merger, which the Board and the management have failed to effectuate. With a high-potential asset base, we strongly recommend the election of leaders who will explore and develop the said potential to redeem EQT from its dismal stock performance.,,We are convinced that the [Rice Team's] 100-day plan will work towards the benefit of the Company and its shareholders. With a set of nominees with the right mix of skills, qualifications, and expertise in operations, we believe that the [Rice Team] Nominees will help EQT achieve the goal of being a low-cost natural gas company and improve its operational performance."

07:13 EDT Osram supports EUR 3.4B takeover offer from Bain, Carlyle Group - Osram announced that after detailed discussions, a bidding consortium composed of Bain Capital and The Carlyle Group, has presented to its Managing Board and Supervisory Board a legally binding transaction offer for the public takeover of all the shares of Osram. The Managing Board and Supervisory Board "have decided to support this offer." "Bain and Carlyle are the right partners for Osram at the right time," said Olaf Berlien, CEO of Osram. "They support our strategy and facilitate growth. Both are committed to our employees and offer shareholders an attractive premium." As part of the public takeover offer, shareholders are to be offered 35 euros per share in cash. This represents a premium of roughly 21% above the last closing price of Osram shares before the publication of Osram's ad-hoc announcement with regards to the evaluation of a legally binding transaction offer by Bain and Carlyle, 2019 and a premium of 22.6% on the volume-weighted average price of Osram shares in the past three months. The offer values Osram at an equity value of 3.4B euros and an enterprise value of roughly 4B euros. Bain and Carlyle have announced a minimum acceptance threshold of 70%. This threshold does not include the shares owned by Osram Licht AG itself. The offer period is expected to end at the beginning of September. The Managing Board intends to sell its own Osram shares to the bidders as part of the takeover.

07:08 EDT Franklin Financial Network announces Steve Groom as general counsel - Franklin Financial Network announced that Steve Groom has joined the company as general counsel and executive VP. Groom has more than 40 years of experience as an attorney and comes most recently from the Nashville law firm of Neal & Harwell. In addition to the time he spent with private law firms, Steve has spent more than 27 years in executive and general counsel roles with two public companies.

06:49 EDT BMW CEO Harald Kruger will not seek second term - The Chairman of the Board of Management of BMW AG, Harald Kruger, gave notice that he will not seek a second term of office. The Supervisory Board will address the matter of a successor during its next meeting on 18 July 2019. Until a decision has been made, Harald Kruger will hold his position as Chairman of the Board of Management. Reference Link

06:04 EDT SemGroup, DCP Midstream announce extension of open season on NGL pipeline - Due to ongoing shipper interest, SemGroup (SEMG) and DCP Midstream (DCP) have announced the commencement of a supplemental open season for natural gas liquids, or NGL, transportation service on the Wattenberg Pipeline, White Cliffs Pipeline, and Southern Hills Pipeline, which will connect Weld County, Colorado to Mont Belvieu, Texas. SemGroup is currently converting a portion of White Cliffs to NGL service and expects it to be in service in Q4. When combined with Southern Hills Pipeline, the system provides DJ Basin customers with increased NGL takeaway capacity and open access to the Texas Gulf Coast markets. SemGroup owns 51% of White Cliffs Pipeline and is the operator. DCP owns 100% of Wattenberg Pipeline and 66% of Southern Hills Pipeline and is the operator of both pipelines. Service will be provided under a published joint tariff between the two carriers. The open season will provide prospective shippers an opportunity to make long-term ship-or-pay volume commitments by executing transportation services agreements with White Cliffs and DCP, in exchange for incentive transportation rates. The terms and conditions of service being made available during this open season extension are the same as those made available to shippers during the initial open season held in May 2018.

05:52 EDT Ipsen announces preliminary data from Phase 1/2 pancreatic cancer study - Ipsen (IPSEY) and Servier announced preliminary data from the Phase 1/2 study of the investigational use of liposomal irinotecan in combination with 5- fluorouracil/leucovorin and oxaliplatin in study patients with previously untreated metastatic pancreatic ductal adenocarcinoma cancer. The results, which were presented as a short oral presentation, included preliminary safety and efficacy data from an ongoing multicenter, open-label, dose-escalation study, which aims to determine the maximum tolerated dose and the recommended dose to be used in future clinical studies. As of the February 19 data cut off, a total of 56 study patients were enrolled and dosed at 15 sites across the US, Spain and Australia. Best overall response) was one complete response, 10 partial responses in 31.3% and 15 stable diseases in 46.9%. 71.9% of study patients in the 50/60 PP achieved disease control at 16 weeks, added the company. Overall, 34% of study patients had a response. Further, there we no reported Grade 3 or higher fatigue or peripheral neuropathy. One study participant in the Part 1A-cohort B dose exploration phase reported a febrile neutropenia. Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients in the 50/60 PP. At data cut-off, 15/32 study patients in the 50/60 PP remained on treatment.

05:45 EDT Celyad presents preliminary interim data from SHRINK, alloSHRINK trials - Celyad announced that Professor Dr. Eric Van Cutsem from the University Hospital of Leuven presented preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials assessing safety and clinical activity of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer. Following the oral and poster presentations at WCGIC, Celyad's management team will host a conference call to discuss the initial clinical results from the SHRINK and alloSHRINK trials. To date, nine mCRC patients have been enrolled as part of the dose-escalation, SHRINK Phase 1 trial evaluating CYAD-01 administered concurrently with FOLFOX chemotherapy. Patient enrollment included four neoadjuvant first-line treatment CRC patients with resectable liver metastasis and five non-resectable mCRC patients with prior multiple chemotherapy lines including FOLFOX and/or FOLFIRI chemotherapy. The mean number of prior therapies received for the relapsed/refractory mCRC patients enrolled was three. Treatment with CYAD-01 with standard FOLFOX chemotherapy was generally well-tolerated, with no reports of cytokine release syndrome grade 2 or higher, related serious adverse events, dose-limiting toxicities, nor on-target off-tumor toxicity, according to Celyad. Preliminary data show a dose-dependent effect on the kinetics of cells with higher levels of cell engraftment at higher doses of CYAD-01 doses, it added. Of the nine mCRC patients, one neoadjuvant patient experienced a partial response according to RECIST 1.1 criteria and a total of six patients experienced stable disease at month three, including two neoadjuvant and four relapsed/refractory mCRC patients. To date, a total of six patients with relapsed/refractory mCRC have been enrolled in the two first dose-level in the alloSHRINK Phase 1 trial. No clinical evidence of graft-versus-host disease have been observed. Further, "Encouraging anti-tumor activity was observed in one patient experiencing a partial response (PR) and three patients experiencing stable disease at month 3," added Celyad.

05:39 EDT Tilray announces expansion of European team with four hires - Tilray announces the expansion of its European leadership team with the appointment of Arne Wilkens as Vice President, Business Expansion, Europe; Jose Tempero as Medical Affairs Director, Europe; Maike Gerlach as Vice President, Marketing, Europe; and Nadja Frenzel as Vice President, Commercial Development, Europe. In addition, Natalie Bucceri joins Tilray's international team as Director, Global Portfolio Expansion. The company explained," The new senior appointments will work collaboratively with Tilray's robust team of experts across the globe to accelerate the company's aggressive European and international expansion strategy. Tilray's multi-faceted EU Campus in Portugal, which recently received its manufacturing license and Good Manufacturing Practices certification, will serve as the primary hub for the cultivation, processing, research and distribution of branded Tilray products throughout Europe and other international markets."